Home > Insider Trading > Filing (0000899243-18-022726)

Filing Details

Accession Number:: 0000899243-18-022726
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2018-08-17 17:44:55
Reporting Period:: 2018-08-07

Accepted Time:: 2018-08-17 17:44:55
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
861838	Idera Pharmaceuticals Inc.	IDRA	Biological Products, (No Disgnostic Substances) (2836)	043072298

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1534425	Pillar Pharmaceuticals I Lp	Pillar Invest Offshore Sal, Starco Ctr, Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	No	No	Yes	No
1534428	Pillar Invest Corp	C/O Idera Pharmaceuticals, Inc. 167 Sidney Street Cambridge MA 02139	No	No	Yes	No
1562069	Pillar Pharmaceuticals Ii, L.p.	Pillar Invest Offshore Sal, Starco Ctr, Bloc B, 3Rd Floor, Omar Daouk Street Beirut M8 2020-3313	No	No	Yes	No
1576891	Pillar Pharmaceuticals Iii, L.p.	Pillar Invest Offshore Sal Starco Ctr, Bloc B, 3Rd Floor Omar Daouk Street Beirut M8 2020-3313	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2018-08-07	91,893	$5.55	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-07	75,000	$5.62	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-08	8,107	$5.89	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-08	50,000	$5.88	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-08	20,000	$5.98	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-09	15,000	$6.25	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-09	25,000	$6.29	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2018-08-09	15,000	$6.35	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $5.4000-$5.7509. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar Pharmaceuticals II, L.P. ("Pillar II"). Pillar Invest Corporation ("Pillar GP") disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. Following this transaction, Pillar II owns directly 697,092 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $5.3800-$5.8000. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Participations Besancon. Participations Besancon is a fund advised by Pillar GP. Pillar GP disclaims Section 16 beneficial ownership of the Besancon Warrants and the common stock underlying such warrants and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, resulting from fees payable to Pillar GP in its capacity as investment advisor to Besancon. Following this transaction, Participations Besancon owns directly 1,061,212 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $5.8300-$6.0000. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar II. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. Following this transaction, Pillar II owns directly 688,985 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $5.6300-$6.1100. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar Pharmaceuticals III, L.P. ("Pillar III"). Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. Following this transaction, Pillar III owns directly 308,980 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $5.9500-$6.0000. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar Pharmaceuticals I, L.P. ("Pillar I"). Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. Following this transaction, Pillar I owns directly 241,266 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $6.1600-$6.3200. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar II. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar II and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar II. Following this transaction, Pillar II owns directly 673,985 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $6.1600-$6.4300. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar I. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar I and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar I. Following this transaction, Pillar I owns directly 216,266 shares of common stock of the Issuer.
The shares sold on this date were sold in multiple transactions. This price is the weighted average sales price per share of all shares sold on this date; the actual sale prices per share range from $6.3000-$6.4000. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Shares sold by Pillar III. Pillar GP disclaims Section 16 beneficial ownership of the securities beneficially owned by Pillar III and this report shall not be deemed an admission that Pillar GP is the Section 16 beneficial owner of any such securities, except to the extent of its pecuniary interest therein, if any, by virtue of its ownership interest in Pillar III. Following this transaction, Pillar III owns directly 293,980 shares of common stock of the Issuer.